KRAS and cancer: Together, these results suggest that targeting transcription via dual inhibition of TOP1 and BRD4 can specifically target KRAS- and MYC-driven pancreatic tumors and provide viable and clinically applicable therapy for hard-to-treat cancer entities such as PDAC and panNEC.